OPPapers.com Essay Index >> Business >> Biopure Oxyglobin Launch
We have many free term papers and essays on Biopure Oxyglobin Launch. We also have a wide variety of research papers and book reports available to you for free. You can browse our collection of term papers or use our search engine.
Biopure Oxyglobin Launch Company: Biopure's greatest strength lies in its ability to market its blood substitute technology for both animal and human use. Further,
Biopure BIOPURE PAPER Recommendation: I strongly recommend that Biopure launch Oxyglobin immediately at a price of $150.00 and initially focus principally on large
Biopure Biopure just received FDA approval for commercial release of Oxyglobin as a veterinary blood substitute. However, the launching of Oxyglobin is directly
biopure swot analysis Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new blood substitute based treatment
(Oxyglobin) blood substitutes. Biopure is faced with the decision of whether to immediately launch Oxyglobin (Og) or wait until after the launch of hemapure (Hp),
Submitted by lucre888 on December 7, 2005
Category: Business
Words: 1956 | Pages: 8
Views: 505
Popularity Rank: 22,063
Average Member Grade: N/A (Add a Comment / Grade this Paper)
Company:
Biopure's greatest strength lies in its ability to market its blood substitute technology for both animal and human use. Further, Biopure has the patents and FDA approval to forge ahead in the animal market with a two-to-five year time buffer from new competition (using similar technology). One of the company's weaknesses is that it has not received FDA approval on Hemopure, and there are two other companies that could beat Biopure to the market with similar products. But if the FDA does not approve Hemopure, which could have the potential to cripple a single product biopharmaceutical company, the company may still withstand such a disruption with Oxyglobin sales and future research and development. Another weakness is the uncertainty of market acceptance for Hemopure, in the face of a deeply-rooted blood donation network.
Biopure has the potential to lead the market with blood substitutes for human and animal use. With Hemopure on the fringe of FDA approval, one of the largest challenges for Biopure is deciding how Oxyglobin will affect the launch of Hemopure. First, it is important to decide whether the market will accept Hemopure at a price point that is substantially greater than Oxyglobin. This concern is accentuated because the two products are almost identical in physical properties and appearance, and hospitals and insurance firms will require a justification for the price differential.
Second, Biopure colleagues are growing anxious to take the company public in the near future. The desire to go public seems to support the immediate release of Oxyglobin to start paying the costs associated with both Oxyglobin and Hemopure, capture market share in the animal and human use blood substitute markets, and alleviate investor concerns regarding the future success as Hemopure.
Customers:
For Hemopure, potential customers all stem from the hospital, which includes emergency medical...
You must Login to view the entire paper.
If you are not a member yet, Sign Up for free!